Key Takeaways
Pomerantz LLP has filed a class-action lawsuit against Atara Biotherapeutics, Inc. (NASDAQ: ATRA), alleging the company violated federal securities laws by making misleading statements to investors over a nearly 19-month period.
According to the lawsuit filed in the United States District Court for the Central District of California, the company made false and/or misleading statements and/or failed to disclose key information. The suit alleges that "certain manufacturing issues, as well as deficiencies inherent in the ALLELE study, made it unlikely that the U.S. Food and Drug Administration ('FDA') would approve the tabelecleucel Biologics License Application ('BLA')."
The legal action, docketed under 26-cv-03083, claims that Atara overstated the regulatory prospects for its lead drug candidate, tabelecleucel. The lawsuit further alleges these manufacturing issues subjected Atara to heightened regulatory scrutiny and jeopardized its ongoing clinical trials, which was likely to have a significant negative impact on the company's financial condition.
The class action seeks to recover damages for investors who purchased Atara securities between May 20, 2024, and January 9, 2026. A lead plaintiff is a representative party acting on behalf of other class members, and the deadline to move the Court to serve as lead plaintiff is May 22, 2026.
The filing of this lawsuit signals potential legal and financial headwinds for Atara Biotherapeutics, as it must now defend against allegations of misleading investors. Investors will be watching for the company's formal response and any subsequent court filings ahead of the May 2026 lead plaintiff deadline.
This article is for informational purposes only and does not constitute investment advice.
